ARVs: The next generation. Going boldly together to new frontiers of HIV treatment

Global Health Science and Practice

Volumn 3, Issue 1, 2015, Pages 1-11

  Barnhart, Matthew ^a   Shelton, James D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

HIV INFECTIONS; HUMAN;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS;

EID: 84961529529     PISSN: None     EISSN: 2169575X     Source Type: Journal    
DOI: 10.9745/GHSP-D-14-00243     Document Type: Review

References (25)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fasttrack: Ending the AIDS epidemic by 2030. Geneva: UNAIDS; 2014. Available from: Http://www.unaids.org/sites/default/ files/media-asset/JC2686-WAD2014report-en.pdf
2. UNAIDS. Fact sheet. Geneva: UNAIDS; 2014. Available from: Http://www.unaids.org/en/resources/campaigns/2014/ 2014gapreport/factsheet
3. Menzies NA, Berruti AA, Blandford JM. The determinants of HIV treatment costs in resource limited settings. PLoS One. 2012; 7(11):e48726. CrossRef. Medline
4. Supply Chain Management System (SCMS) [Internet]. Arlington (VA): SCMS. E-catalog: ARVs; updated Nov 2014 [cited 2015 Jan 13]; [about 4 screens]. Available from: Http://scms.pfscm. org/scms/ecatalog/arvs
5. Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2014;17(1). Medline
6. Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C; participants of Conference on Antiretroviral Drug Optimization. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resourcelimited settings: A consensus statement. Lancet Infect Dis. 2012;12(7):550-60. CrossRef. Medline
7. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818. CrossRef. Medline
8. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21-27. CrossRef. Medline
9. The Second Conference on Antiretroviral Dose Optimization (CADO 2); Cape Town, South Africa; 16-18 Apr 2013. Meeting report. Available from: Http://hivtreatmentoptimization.org/ sites/default/files/documents/2010-11/cado2meetingreport finaljuly2013.pdf
10. Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449-455. CrossRef. Medline
11. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52-58. CrossRef. Medline
12. US Department of Health and Human Services, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases [Internet]. Bethesda (MD): NIH; last updated 2015 Jan 8. NIHsponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission; 2014 Nov 17 [cited 2015 Jan 6]; [about 2 screens]. Available from: Http://www.niaid.nih.gov/ news/newsreleases/2014/Pages/HIVprevention.aspx
13. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204-1214. CrossRef. Medline
14. Bermudez J, 't Hoen E. The UNITAID patent pool initiative: Bringing patents together for the common good. Open AIDS J. 2010;4:37-40. Medline
15. Medicines Patent Pool [Internet]. Geneva: MPP. Medicines Patent Pool, ViiV Healthcare sign licence for the most recent HIV medicine to have received regulatory approval; 2014 Apr 1 [cited 2015 Jan 6]; [about 2 screens]. Available from: Http:// www.medicinespatentpool.org/medicines-patent-pool-viivhealthcare-sign-licence-for-the-most-recent-hiv-medicine-tohave-received-regulatory-approval/
16. Medicines Patent Pool [Internet]. Geneva: MPP. The Medicines Patent Pool (MPP) broadens collaboration with Gilead Sciences: Signs licence for phase III medicine tenofovir alafenamide (TAF); 2014 Jul 24 [cited 2015 Jan 6]; [about 2 screens]. Available from: Http://www.medicinespatentpool.org/the-medicinespatent-pool-mpp-broadens-collaboration-with-gilead-sciencessigns-licence-for-phase-iii-medicine-tenofovir-alafenamide-taf/
17. Viiv Healthcare [Internet]. Middlesex (UK): ViiV Healthcare; c2015. ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1; 2014 Jun 12 [cited 2015 Jan 6]; [about 6 screens]. Available from: Http://www.viivhealthcare.com/ media/press-releases/2014/june/viiv-healthcare-announcesnew-collaboration-with-janssen.aspx
18. Achhra AC, Boyd MA. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature. AIDS Res Ther. 2013;10(1):33. CrossRef. Medline
19. Margolis D, Brinson C, Eron J, Richmond G, LeBlanc R, Griffith S, et al. 744 and rilpivirine as two-drug oral maintenance therapy: LAI116482 (LATTE) week 48 results. Abstract No. 91LB. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014Mar 3-6; Boston, MA. Abstract available from: Http://www.croiconference.org/sessions/744-and-rilpivirine-twodrug-oral-maintenance-therapy-lai116482-latte-week-48-results
20. Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Keikawus A, Hoffmann C, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J Int AIDS Soc. 2014;17(4 Suppl 3):19532. CrossRef. Medline
21. Feng M, Wang D, Grobler J, Hazuda DJ, Miller MD, Lai MT. In vitro resistance selection with doravirine (MK-1439): A novel non-nucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59(1):590-598. CrossRef. Medline
22. Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151-1154. CrossRef. Medline
23. Radzio J, Spreen W, Yueh YL, Mitchell J, Jenkins L, Garcia-Lerma JG, et al. Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures. Abstract No. 40LB. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3-6; Boston, MA. Abstract available from: Http://www.croiconference.org/ sessions/monthly-gsk744-long-acting-injections-protectmacaques-against-repeated-vaginal-shiv
24. SpreenW, Ford SL, Chen S, Wilfret D, Margolis D, Gould E, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67(5):481-486. CrossRef. Medline
25. Clinton Health Access Initiative (CHAI). Antiretroviral (ARV) ceiling price list. Boston: CHAI; 2013. Available from: Http:// www.clintonhealthaccess.org/files/CHAI%20ARV%20 Ceiling%20Price%20August%202013.pdf